An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox–Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy.

PART 01: Executive summary

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Infantile spasm: Overview

PART 06: Market landscape

Global infantile spasms therapeutics market

Five forces analysis

PART 07: Market segmentation by dosage form

Solid

Liquid

PART 08: Market segmentation by ROA

Oral

Parenteral

PART 09: Geographical segmentation

Infantile spasms therapeutics market in Americas

Infantile spasms therapeutics market in EMEA

Infantile spasms therapeutics market in APAC

PART 10: Market drivers

Major drugs launch expected in 2017-2021

Growing scientific advancements in diagnostics

Special regulatory designations

PART 11: Impact of drivers

PART 12: Market challenges

Growing usage of seizure management devices, a threat

to drug therapies

Limited patient population

Moderate pipeline

PART 13: Impact of drivers and challenges

PART 14: Market trends

Development of devices and smartphone apps to detect

seizures and track medications

Alternate drugs fill the gap

Reformulation of marketed drugs

PART 15: Vendor landscape

Competitive scenario

Other prominent vendors

PART 16: Key vendor analysis

H. Lundbeck

Mallinckrodt Pharmaceuticals

INSYS Therapeutics

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio